This multifaceted aspects of IL-1α functions implicated that it is critical to target IL-1α isoforms precisely for immunotherapy, though anakinra (Kineret; Amgen/Biovitrum), the IL-1R antagonist protein has already been approved by the FDA and has shown promising results for treating patients with rheumatoid arthritis and auto-immune diseases [103,104]. This evidence concerns the gene IL1R1 and rheumatoid arthritis.